Haegarda denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for haegarda are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Haegarda as Duplicate Therapy — and Why You Can Appeal

Haegarda (C1 esterase inhibitor subcutaneous) is a prophylactic treatment for hereditary angioedema (HAE). Cigna may issue a duplicate-therapy denial when it identifies another HAE prophylactic already on your profile — such as a prior C1-INH product, a plasma kallikrein inhibitor, or a bradykinin-receptor blocker — and concludes that Haegarda provides no additional clinical benefit over what you are already receiving.

This denial is frequently incorrect or incomplete. Different HAE prophylactics have distinct mechanisms, routes of administration, and patient-specific tolerability profiles. A prescriber may have sound clinical reasons for transitioning between agents or for choosing Haegarda specifically. The denial does not automatically mean the two therapies are clinically interchangeable for your situation.

## Your Federal Appeal Rights

• Internal appeal: You have the right to a full internal appeal under ERISA §503 (employer-sponsored plans) or state insurance law. Submit within the timeframe printed on your denial letter — typically 180 days.
• External review: After exhausting internal appeals (or if Cigna takes too long to decide), you may request an Independent Review Organization (IRO) review under ACA §2719. The external-review window is generally open for approximately four months after final internal denial. Expedited external review — with a decision in as little as 72 hours — is available when your health is at serious risk.

## Concrete Appeal Steps

1. Request the complete denial letter and Cigna's applicable coverage/medical policy in writing. 2. Have your prescriber document the specific clinical rationale for choosing Haegarda over or instead of any other agent on file, including why the alternative does not adequately control your HAE. 3. Obtain a detailed medical-necessity letter from your prescriber addressing Cigna's duplicate-therapy criteria point by point. 4. Compile your HAE diagnosis records, attack frequency/severity logs, and any prior-treatment history with documented outcomes. 5. Submit the internal appeal with all documentation attached.

## Documentation to Gather

• Confirmed HAE diagnosis (genetic or complement testing, specialist note)
• Chronological treatment history: every prophylactic tried, duration, response, and reason for discontinuation or transition
• Attack frequency and severity records (emergency visits, hospitalizations, quality-of-life impact)
• Prescriber letter explaining why Haegarda is clinically distinct and necessary for this patient
• Any relevant specialty-society guidance (e.g., the US Hereditary Angioedema Association clinical guidelines) cited generically

## Criteria-Mapping Structure

Pull Cigna's current medical policy for Haegarda and list every criterion. For each one, write the exact chart fact that satisfies it. For example: if the policy requires documented inadequate response to a prior agent, cite the chart note date, the agent used, and the documented outcome. This one-to-one mapping is the single most persuasive element of a successful appeal.